---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-000065"
form_type: "8-K"
ticker: "BICX"
cik: "0001443863"
company_name: "BioCorRx Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:02:59.528551+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCorRx President Brady Granier resigns; Louis Lucido appointed as President

## Summary
- Brady Granier resigned as President of BioCorRx and CEO of BioCorRx Pharmaceuticals, effective Jan 31, 2024; remains on board.
- Louis Lucido appointed Interim President from Jan 5, 2024, then President from Feb 1, 2024; remains board member.
- Lucido to receive $200,000 annual compensation paid in equity monthly (~$16,667 in shares based on 3-day avg closing price).
- Lucido, 75, formerly COO of DoubleLine Group and founding partner; director since March 2019.
- Granier's resignation not due to any disagreement with the company.

## SEC filing metadata
- accession: 0001477932-24-000065
- form_type: 8-K
- ticker: BICX
- cik: 0001443863
- company_name: BioCorRx Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1443863/000147793224000065/0001477932-24-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1443863/000147793224000065/bicx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-000065
- JSON: https://secwatch.observer/filing/0001477932-24-000065.json
- Plain text: https://secwatch.observer/filing/0001477932-24-000065.txt

## Key facts
- Executive change
  Louis Lucido was appointed as President at BioCorRx Inc..
  - Action: appointed
  - Role: President
  source text: On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1443863/000147793224000065/0001477932-24-000065-index.htm
- Executive change
  Brady Granier resigned as President at BioCorRx Inc..
  - Action: resigned
  - Role: President
  source text: On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. (the “ Company ”) and Chief Executive Officer of BioCorRx Pharmaceuticals, a subsidiary of the Company, effective January 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1443863/000147793224000065/0001477932-24-000065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.